Tusamitamab Ravtansine (SAR408701) in Combination With Ramucirumab in Pretreated Participants With Gastric Cancer
A legfontosabb adatok
- Ki végzi
- Sanofi
- Hol
- Belgium, Dél-Korea, Japán, Oroszország, Spanyolország és Törökország21 helyszín, 6 országbanVálassz országot a helyszínekhez
- Azonosító
- NCT05071053
- EudraCT 2021-001967-26
- U1111-1266-5040
- Állapot
- Leállítva
- Fázis
- 2. fázis
- Résztvevők
- 35 fő vett részt
- Kezdés
- 2021. nov. 16.
- Befejezés
- 2024. nov. 5.
- A vizsgálat típusa
- Beavatkozással járó
- A vizsgált kezelések
- Ramucirumab (CYRAMZA®)
- Tusamitamab ravtansine (SAR408701)
- A regiszteradat frissítve
- 2025. augusztus 22.
- Miért állt le
- Sponsor decision, the decision is not related to any safety concern.
Ki vehet részt
- Életkor
- 18 év felett
- Nem
- Nők és férfiak
- Egészséges önkéntesek
- Nem vehetnek részt
A regiszter feltételei, szó szerint
Mind a 28 feltétel megnézéseKevesebb
Ki vehet részt
- Histologically or cytologically confirmed diagnosis of gastric or GEJ adenocarcinoma
- Metastatic disease or locally advanced, unresectable disease
- Participants who have measurable target lesion
- Participants with high carcinoembryonic antigen-related cell adhesion molecule (CEACAM5) expression as per central assessment on tumor biospsy
- Eastern Cooperative Oncology Group (ECOG) performance status 0-1
- Female participant who agrees to use effective contraceptive methods during and for at least 7 months after the last dose of treatment administration
- Male participant who agrees to use effective contraception methods during and for at least 4 months after the last dose of treatment administration
- Signed informed consent
Ki nem vehet részt
- Significant concomitant illness
- Nonresolution of any prior treatment-related toxicity
- Unresolved corneal disorder or any previous corneal disorder considered by an ophthalmologist to predict higher risk of drug-induced keratopathy
- Major surgery within 28 days prior to Day 1/first IMP infusion; subcutaneous venous access device placement within 7 days prior to Day 1; or postoperative bleeding complications or wound complications from a surgical procedure performed in the last 2 months
- History of gross hemoptysis (defined as bright red blood or ≥1/2 teaspoon) within 2 months before the first treatment administration
- Any arterial thrombotic event, including myocardial infarction, unstable angina, cerebrovascular accident, or transient ischemic attack, within 6 months before the first administration of treatment administration
- Serious or nonhealing wound, skin ulcer, or bone fracture within 28 days before the first administration of treatment administration
- Gastrointestinal (GI) perforation and/or fistulae within 6 months prior to first administration of treatment administration
- Significant bleeding disorders, vasculitis, or Grade 3-4 gastrointestinal (GI) bleeding within 3 months before the first administration of study intervention
- Medical condition requiring concomitant administration of a medication with a narrow therapeutic window and metabolized by CYP450 or a strong CYP3A inhibitor
- Concurrent treatment with any other anticancer therapy
- Prior treatment targeting CEACAM5 or containing maytansinoid DM1 or DM4 or ramucirumab or taxane or targeting VEGF/VEGFR Poor organ function; The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial
- Untreated brain metastases, leptomeningeal disease, or uncontrolled spinal cord compression
- History within the last 3 years of an invasive malignancy other than that treated in this study
- Known uncontrolled infection
- History of uncontrolled hereditary or acquired thrombotic disorder or history of aneurism
- Uncontrolled arterial hypertension (systolic ≥150 mmHg or diastolic ≥90 mmHg) despite standard medical management
- Bowel obstruction, history or presence of inflammatory enteropathy or extensive intestinal resection Crohn's disease, ulcerative colitis, or chronic diarrhea
- Use of contact lenses
- Radiographic evidence of major airway or blood vessel invasion or intratumor cavitation
Ennek a vizsgálatnak nincs helyszíne itt: Egyesült Államok.
6 országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.
A vizsgálatról
Mit akar kideríteni a vizsgálat
Primary Objectives:
A teljes eredeti leírásKevesebb
Part 1: to confirm the recommended tusamitamab ravtansine loading dose Q2W in combination with ramucirumab in advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma population
Part 2: to assess the antitumor activity of tusamitamab ravtansine loading dose Q2W in combination with ramucirumab in advanced gastric or GEJ adenocarcinoma
Secondary Objectives:
* To assess safety and tolerability * To assess durability of response (DOR) * To assess progression-free survival (PFS) * To assess the disease control rate (DCR) * To assess the pharmacokinetics (PK) * To assess the immunogenicity
A vizsgálat csoportja
- Tusamitamab ravtansine+RamucirumabA vizsgált kezelés
Participants received ramucirumab 8 milligram/kilogram (mg/kg) via intravenous (IV) infusion followed by tusamitamab ravtansine loading dose at 170 mg/meter square (m\^2) via IV infusion on Cycle 1 Day 1 (each cycle was 2 weeks); and then ramucirumab 8 mg/kg via IV infusion followed by tusamitamab ravtansine 100 mg/m\^2 via IV infusion at Cycle 2 and every 2 weeks (Q2W) in all subsequent cycles until disease progression, unacceptable adverse event (AE), death, initiation of a new anticancer therapy, or the participant's or investigator's decision to stop the treatment.
Kezelés: Ramucirumab (CYRAMZA®) és Tusamitamab ravtansine (SAR408701)
Adatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on.
- Hivatalos cím
- Open-label Study of Tusamitamab Ravtansine (SAR408701) in Combination With Ramucirumab in Participants Previously Treated for Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma With CEACAM5-positive Tumors
- A regiszteradat frissítve
- 2025. augusztus 22.